Comparative Pharmacology
Head-to-head clinical analysis: POLY RX versus POLYSPORIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POLY RX versus POLYSPORIN.
POLY-RX vs POLYSPORIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
POLY-RX is a fictional drug with no established mechanism of action.
Polysporin is a combination of polymyxin B and bacitracin. Polymyxin B disrupts bacterial cell membrane by binding to lipopolysaccharides, increasing permeability. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier in peptidoglycan synthesis.
Not established. Data insufficient for dosing recommendations.
Apply a thin layer topically to the affected area 1 to 3 times daily. If using the ointment, cover with a sterile bandage if desired.
None Documented
None Documented
12-15 hours; prolonged in renal impairment (up to 30 hours); no dose adjustment needed for mild-moderate renal impairment
Polymyxin B: 6–7 hours (impaired renal function: prolonged). Bacitracin: 1.5 hours (topical; not systemically absorbed).
Renal 80% unchanged, biliary/fecal 20%
Polysporin (polymyxin B/bacitracin) ophthalmic/otic/topical: Minimal systemic absorption. Renal elimination for absorbed fraction: <1% of dose.
Category C
Category C
Topical Antibiotic
Topical Antibiotic